Search
Liver Metastases Clinical Trials
A listing of 13 Liver Metastases clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 13 of 13
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Liver Metastases
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 13 active clinical trials seeking participants for Liver Metastases research studies. The states with the highest number of trials for Liver Metastases participants are Ontario, California, New York and Pennsylvania.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
CapTem Plus Radioembolization for NET Liver Metastases
Recruiting
Grade 2 neuroendocrine tumors have an intermediate rate of progression following embolotherapy of liver metastases. The combination of capecitabine and temozolomide has been shown to be an active regimen in this disease. Both drugs are radiosensitizers, and in a safety and feasibility study were combined with yttrium-90 radioembolization with acceptable additive toxicities and better than expected response and duration of disease control. This study expands use of this regimen in a Phase 2 inves... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/01/2021
Locations: Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Neuroendocrine Tumor Grade 2, Liver Metastases
13 - 13 of 13